SCHEMBL3013356

SCHEMBL3013356

CC(C)c1cc(C(C)C)c(S(=O)(=O)C2CCN(c3nc(-c4cc(F)cc(F)c4)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.42
SMN1; SMN2 Q16637 10/20 0.41
RAB9A P51151 8/20 0.41
NPC1 O15118 7/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
ALDH1A1 P00352 3/20 0.39
AR P10275 2/20 0.37
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 2/20 0.37
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022463 0.94 SMN1; SMN2 (0.40) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL3010548 0.89 SMN1; SMN2 (0.41) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL3014309 0.89 SMN1; SMN2 (0.43) MAPK1SMN1; SMN2RAB9ANPC1ITGB2
SCHEMBL3012873 0.88 MAPK1 (0.42) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL3019653 0.87 MAPK1 (0.52) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL3010531 0.87 SMN1; SMN2 (0.44) MAPK1SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3017646 0.86 SMN1; SMN2 (0.53) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL3002616 0.86 MAPT (0.51) MAPK1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL3009361 0.86 AR (0.42) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL3003088 0.86 AR (0.42) MAPK1SMN1; SMN2RAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957490-B1 NOVEL INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC COMPOSITIONS COMPRISING SAME SANOFI AVENTIS (FR) 2010-01-06 EP claimed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.